National Investor Network
Special Situation Letter
A Private Message for Independent Investors
Are Pesticides the New Tobacco?
Why an industry the world cannot live without may be approaching a change it can no longer avoid…
Dear Investor,
I want to ask you a strange question.
What happens when the public turns against the products of a giant industry… but the world still needs the job those products perform?
That is not a theoretical question.
We have watched versions of this story before. For years, tobacco appeared untouchable. It was profitable, familiar and woven into everyday American life.
Then the pressure started building.
Scientific concern. Public scrutiny. Lawsuits. Regulation. A slow but unmistakable change in what consumers would accept.
Tobacco demand could fall because people could stop smoking.
|
But people cannot simply stop controlling mosquitoes, termites, roaches, ticks and the pests that threaten homes, businesses, food and public health. |
That is what makes today’s pesticide story so interesting.
If traditional chemical products face mounting pressure, the need does not go away. The money does not necessarily disappear. It may begin moving toward a different kind of solution.
And quietly – well outside the spotlight of most Wall Street research – one small private company has spent years developing botanical pest-control products designed for this changing market.
That company is Med-X, Inc. It has reserved MXRX for possible use following a successful future Nasdaq listing.
I am not asking you to buy a stock. I am asking you to examine a question before the answer becomes obvious to everyone else:
If pesticides are entering their “tobacco moment,” where could the demand go next?
We prepared a detailed report that follows the entire story – from the historical comparison, to the unavoidable demand for pest control, to the botanical category and the company attempting to build inside it.
The report is long. Deliberately so. It gives you the argument, the counterarguments and the facts you should investigate for yourself.
Click here now to read “Are Pesticides the New Tobacco?”
You may agree with the comparison. You may reject it. Either way, this is a market transition worth understanding.
Sincerely,
The Editors
National Investor Network
P.S. The most consequential changes often look gradual – until suddenly they do not. Read the full investor letter here and decide for yourself whether pest control is approaching one of those moments.
|
Chip Stocks Snapped a 2008-Era Losing Streak. Now They Need Earnings to Prove It.
One day does not erase three weeks of damage, but Monday’s move in semiconductor stocks was at least hard to ignore. The Philadelphia Semiconductor Index rose 1.6%, snapping an eight-session losing streak and its longest string of consecutive declines since October 2008. Over those eight sessions, the SOX had fallen roughly 15.7% cumulatively. Memory names led the recovery. SanDisk rose 7.23%, Western Digital gained 5.96%, SK hynix rose 5.07% and Micron added 4.18%. Amazon climbed nearly 5% after Morgan Stanley raised its price target.
The problem is what happened when the US session closed. On October 20, Japanese and South Korean stock markets declined in morning trade, with the KOSPI down more than 3% by 10:30 a.m. in Seoul and the Nikkei 225 down about 0.8%, driven by weak semiconductor shares including Samsung Electronics and SK hynix. South Korean and Japanese investors remained unwilling to rebuild exposure to Asia’s biggest artificial intelligence trades before a crucial earnings week. By 10:30 a.m. Seoul time, overseas funds had sold 605.8 billion won of shares and institutions another 470.7 billion won, with retail buying of 832.1 billion won insufficient to stop the slide.
That divergence matters. When US chip stocks finally catch a bid after a historic sell-off and the region that houses their largest manufacturing partners shrugs, the bounce deserves scrutiny rather than celebration.
HSBC chief multi-asset strategist Max Kettner described Monday’s action plainly: “It is an incredibly technically-driven market.” He does not see any fundamental catalyst, outside of earnings, capable of calming nerves around artificial intelligence concerns. That framing is consistent with what the price action itself showed. Short covering explains a move like that far more convincingly than a genuine rerating.
Historical context cuts both ways. After the previous seven instances when the SOX fell eight or more consecutive sessions since 1994, the index rose the next day all seven times by a median of 1.4%. But one month later it was lower in five of those seven cases, with a median one-month return of negative 5.2% against a typical positive 1.8%. On a six-month view the median gain was just 2%, well below the 9.8% from any random six-month stretch. Monday fit the first part of the pattern. Whether the rest follows depends almost entirely on what Lam Research and Meta report Wednesday night.
Lam Research releases fiscal Q1 2027 results after the close on Wednesday, with analysts expecting earnings of $2.18 per share. The bar is high. Last quarter Lam posted record revenue of $6.72 billion, beating estimates, with gross margin hitting 52% and operating margin reaching 38.4%; the company raised its long-term margin targets and pointed to AI demand across NAND, DRAM, and advanced foundry logic as the driver. Traders need to see guidance hold or improve. Any sign that equipment order visibility is shortening would validate the AI-fatigue thesis that drove the eight-day sell-off.
Meta reports Q3 2026 results also after Wednesday’s close. Key metrics including Family Daily Active People, revenue by segment, and operating income will be closely watched for signs of operating momentum. Investors will track expenses and capital spending, because Meta’s Q2 earnings miss came as costs surged; management has also flagged 2026 capital expenditures of $130 to $145 billion as it builds out AI infrastructure. If Meta’s advertising revenue holds and its AI spending guidance does not surprise to the upside again, the AI-buildout investment case gets a lifeline. If costs run ahead of revenue once more, the sell-off that paused Monday resumes in force.
The SOX broke its losing streak. The more important question is whether Lam and Meta break the uncertainty that caused it. Until those numbers land Wednesday evening, Monday looks more like a position unwind than a verdict.
